BofA lowered its price target for West Pharmaceutical Services (WST) from $370 to $300, while reiterating a Buy rating, following a model update and broader sector pressure. The adjustment came after the company released strong year-end results and better-than-expected FY26 guidance, driven by growth in its non-GLP-1 high-value products. West Pharmaceutical also declared a quarterly dividend of $0.22 per share and authorized a new $1 billion share repurchase program, reinforcing its commitment to shareholder returns.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BofA Cuts West Pharmaceutical (WST) Target Following Model Update and Sector Pressure
BofA lowered its price target for West Pharmaceutical Services (WST) from $370 to $300, while reiterating a Buy rating, following a model update and broader sector pressure. The adjustment came after the company released strong year-end results and better-than-expected FY26 guidance, driven by growth in its non-GLP-1 high-value products. West Pharmaceutical also declared a quarterly dividend of $0.22 per share and authorized a new $1 billion share repurchase program, reinforcing its commitment to shareholder returns.